Metabolism and structure of PDA as the target for new therapies: possibilities and limitations for nanotechnology

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Orth M, Metzger P, Gerum S, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14(1):141. doi: 10.1186/s13014-019-1345-6
   PubMed Web of Science ®Google Scholar
• Mizrahi JD, Surana R, Valle WV, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020. doi: 10.1016/S0140-6736(20)30974-0
   PubMed Web of Science ®Google Scholar
• Ye L, Shi S, Chen W. Innate immunity in pancreatic cancer: lineage tracing and function. Front Immunol. 2022;13:1081919. doi: 10.3389/fimmu.2022.1081919
   PubMed Web of Science ®Google Scholar
• Melstrom LG, Salazar MD, Diamond DJ. The pancreatic cancer microenvironment: a true double agent. J Surg Oncol. 2017;116(1):7–15. doi: 10.1002/jso.24643
   PubMed Web of Science ®Google Scholar
• Murakami T, Hiroshima Y, Matsuyama R, et al. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg. 2019;3(2):130–137. doi: 10.1002/ags3.12225
   PubMed Web of Science ®Google Scholar
• Zhang T, Ren Y, Yang P, et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 2022;13(10):897. doi: 10.1038/s41419-022-05351-1
   PubMed Web of Science ®Google Scholar
• Sunami Y, Häußler J, Kleeff J. Cellular heterogeneity of pancreatic stellate cells, mesenchymal stem cells, and cancer-associated fibroblasts in pancreatic cancer. Cancers (Basel). 2020;12(12). doi: 10.3390/cancers12123770
   PubMed Web of Science ®Google Scholar
• Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266–4276. doi: 10.1158/1078-0432.CCR-11-3114
   PubMed Web of Science ®Google Scholar
• Bannoura SF, Uddin MH, Nagasaka M, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev. 2021;40(3):819–835. doi: 10.1007/s10555-021-09990-2
   PubMed Web of Science ®Google Scholar
• Bryant KL, Mancias JD, Kimmelma AC, et al. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39(2):91–100. doi: 10.1016/j.tibs.2013.12.004
   PubMed Web of Science ®Google Scholar
• Gaglio D, Metallo CM, Gameiro PA, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7(1):523. doi: 10.1038/msb.2011.56
   PubMedGoogle Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406. doi: 10.1056/NEJMoa1809775
   PubMed Web of Science ®Google Scholar
• Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol. 2017;10(8):631–645. doi: 10.1177/1756283X17713879
   PubMed Web of Science ®Google Scholar
• Atiq S, Atiq O, Atiq Z, et al. A case of metastatic pancreatic adenocarcinoma in complete remission using chemotherapy and immunotherapy. Cureus. 2021;13(2):e13133. doi: 10.7759/cureus.13133
   PubMed Web of Science ®Google Scholar
• Koskowska E, Lesnikow A, Pałucki J, et al. Long-term complete remission of pancreatic cancer after first-line chemotherapy with gemcitabine and nab-paclitaxel in a patient with depressive disorder. Oncol Clin Pract. 2020;16(2):83–86. doi: 10.5603/OCP.2020.0016
   Web of Science ®Google Scholar
• Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023;18(1):123–148. doi: 10.1146/annurev-pathmechdis-031621-024600
   PubMedGoogle Scholar
• Ferrara B, Pignatelli B, Cossutta M, et al. The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options. Cancers (Basel). 2021;13(17):4442. doi: 10.3390/cancers13174442
   PubMed Web of Science ®Google Scholar
• Kawada K, Toda K, Sakai Y. Targeting metabolic reprogramming in KRAS-driven cancers. Int J Clin Oncol. 2017;22(4):651–659. doi: 10.1007/s10147-017-1156-4
   PubMed Web of Science ®Google Scholar
• Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27(1):441–464. doi: 10.1146/annurev-cellbio-092910-154237
   PubMed Web of Science ®Google Scholar
• Upadhyay M, Samal J, Kandpal M, et al. The Warburg effect: insights from the past decade. Pharmacol Ther. 2013;137(3):318–330. doi: 10.1016/j.pharmthera.2012.11.003
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi: 10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Dong S, Li W, Li X, et al. Glucose metabolism and tumour microenvironment in pancreatic cancer: a key link in cancer progression. Front Immunol. 2022;13:1038650. doi: 10.3389/fimmu.2022.1038650
   PubMed Web of Science ®Google Scholar
• Sharen G, Peng Y, Cheng H, et al. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget. 2017;8(12):19760–19767. doi: 10.18632/oncotarget.15035
   PubMedGoogle Scholar
• Kurahara H, Maemura K, Mataki Y, et al. Significance of glucose transporter type 1 (GLUT-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;25(5):1432–1439. doi: 10.1245/s10434-018-6357-1
   PubMed Web of Science ®Google Scholar
• Melstrom LG, Salabat M, Ding X, et al. Apigenin down-regulates the hypoxia response genes: HIF-1alpha, GLUT-1, and VEGF in human pancreatic cancer cells. J Surg Res. 2011;167(2):173–181. doi: 10.1016/j.jss.2010.10.041
   PubMed Web of Science ®Google Scholar
• Melstrom LG, Salabat M, Ding X, et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008;37(4):426–431. doi: 10.1097/MPA.0b013e3181735ccb
   PubMed Web of Science ®Google Scholar
• Xu D, Zhou Y, Xie X, et al. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A. Int J Oncol. 2020;57(5):1223–1233. doi: 10.3892/ijo.2020.5120
   PubMed Web of Science ®Google Scholar
• Huang D, Li C, Zhang H. Hypoxia and cancer cell metabolism. Acta Biochim Biophys Sin (Shanghai). 2014;46(3):214–219. doi: 10.1093/abbs/gmt148
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014;4:64. doi: 10.3389/fonc.2014.00064
   PubMedGoogle Scholar
• Elstrom RL, Bauer D, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–3899. doi: 10.1158/0008-5472.CAN-03-2904
   PubMed Web of Science ®Google Scholar
• Hamada S, Matsumoto R, Masamune A. HIF-1 and NRF2; key molecules for malignant phenotypes of pancreatic cancer. Cancers (Basel). 2022;14(2):14(2. doi: 10.3390/cancers14020411
   Web of Science ®Google Scholar
• Cui XG, Han Z, He S, et al. HIF1/2α mediates hypoxia-induced LDHA expression in human pancreatic cancer cells. Oncotarget. 2017;8(15):24840–24852. doi: 10.18632/oncotarget.15266
   PubMedGoogle Scholar
• Yang J, Ren B, Yang G, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol Life Sci. 2020;77(2):305–321. doi: 10.1007/s00018-019-03278-z
   PubMed Web of Science ®Google Scholar
• He G, Jiang Y, Zhang B, et al. The effect of HIF-1alpha on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Asia Pac J Clin Nutr. 2014;23(1):174–180. doi: 10.6133/apjcn.2014.23.1.14
   PubMed Web of Science ®Google Scholar
• Li R, Li H, Zhu L, et al. Reciprocal regulation of LOXL2 and HIF1alpha drives the Warburg effect to support pancreatic cancer aggressiveness. Cell Death Dis. 2021;12(12):1106. doi: 10.1038/s41419-021-04391-3
   PubMed Web of Science ®Google Scholar
• Park JS, Lee J, Lee Y, et al. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis. Oncotarget. 2016;7(27):42539–42552. doi: 10.18632/oncotarget.9918
   PubMedGoogle Scholar
• Buchler P, Reber H, Buchler M, et al. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer. 2004;100(1):201–210. doi: 10.1002/cncr.11873
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao X, Tang H, et al. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells. Urol Int. 2012;88(1):95–101. doi: 10.1159/000331881
   PubMed Web of Science ®Google Scholar
• Xiao Y, Qin T, Sun L, et al. Resveratrol ameliorates the malignant progression of pancreatic cancer by inhibiting hypoxia-induced pancreatic stellate cell activation. Cell Transplant. 2020;29:963689720929987. doi: 10.1177/0963689720929987
   PubMed Web of Science ®Google Scholar
• Romero-Garcia S, Moreno-Altamirano M, Prado-Garcia H, et al. Lactate contribution to the tumor microenvironment: mechanisms, effects on Immune Cells and therapeutic relevance. Front Immunol. 2016;7:52.
   PubMed Web of Science ®Google Scholar
• Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685–3692. doi: 10.1172/JCI69741
   PubMed Web of Science ®Google Scholar
• Rong Y, Wu W, Ni X, et al. Lactate dehydrogenase a is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 2013;34(3):1523–1530. doi: 10.1007/s13277-013-0679-1
   PubMedGoogle Scholar
• Mohammad GH, Damink S, Malago M, et al. Pyruvate kinase M2 And lactate dehydrogenase a are overexpressed in pancreatic cancer and correlate with poor outcome. PLOS ONE. 2016;11(3):e0151635. doi: 10.1371/journal.pone.0151635
   PubMed Web of Science ®Google Scholar
• Le A, Cooper C, Gouw A, et al. Inhibition of lactate dehydrogenase a induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA. 2010;107(5):2037–2042. doi: 10.1073/pnas.0914433107
   PubMed Web of Science ®Google Scholar
• Mohammad GH, Vassileva V, Acedo P, et al. Targeting pyruvate kinase M2 and lactate dehydrogenase a is an effective combination strategy for the treatment of pancreatic cancer. Cancers (Basel). 2019;11(9):11(9. doi: 10.3390/cancers11091372
   Web of Science ®Google Scholar
• Cheng CS, Tan H, Wang N, et al. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Clin Transl Med. 2021;11(6):e467. doi: 10.1002/ctm2.467
   PubMed Web of Science ®Google Scholar
• Payen VL, Mina E, Hee VF, et al. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48–66. doi: 10.1016/j.molmet.2019.07.006
   PubMed Web of Science ®Google Scholar
• Kong SC, Nohr-Nielsen A, Zeeberg K, et al. Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells. Pancreas. 2016;45(7):1036–1047. doi: 10.1097/MPA.0000000000000571
   PubMed Web of Science ®Google Scholar
• Baek G, Tse YF, Hu Z, et al. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 2014;9(6):2233–2249. doi: 10.1016/j.celrep.2014.11.025
   PubMed Web of Science ®Google Scholar
• Singh M, Afonso J, Sharma D, et al. Targeting monocarboxylate transporters (MCTs) in cancer: how close are we to the clinics? Semin Cancer Biol. 2023;90:1–14. doi: 10.1016/j.semcancer.2023.01.007
   PubMed Web of Science ®Google Scholar
• Liu T, Han S, Yao Y, et al. Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) In tumor cells and the tumor microenvironment. Cancer Manag Res. 2023;15:957–975. doi: 10.2147/CMAR.S421771
   PubMed Web of Science ®Google Scholar
• Renner K, Bruss C, Schnell A, et al. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep. 2019;29(1):135–150.e9. doi: 10.1016/j.celrep.2019.08.068
   PubMed Web of Science ®Google Scholar
• Kumstel S, Schreiber T, Goldstein L, et al. Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. PLOS ONE. 2022;17(4):e0266601. doi: 10.1371/journal.pone.0266601
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Hindupur SK, et al. Syrosingopine sensitizes cancer cells to killing by metformin. Sci Adv. 2016;2(12):e1601756. doi: 10.1126/sciadv.1601756
   PubMed Web of Science ®Google Scholar
• Qin C, Yang G, Yang J, et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020;19(1):50. doi: 10.1186/s12943-020-01169-7
   PubMed Web of Science ®Google Scholar
• Zhang J, Pavlova NN, Thompson CB. Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. Embo J. 2017;36(10):1302–1315. doi: 10.15252/embj.201696151
   PubMed Web of Science ®Google Scholar
• Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–105. doi: 10.1038/nature12040
   PubMed Web of Science ®Google Scholar
• Abrego J, Gunda V, Vernucci E, et al. GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Cancer Lett. 2017;400:37–46. doi: 10.1016/j.canlet.2017.04.029
   PubMed Web of Science ®Google Scholar
• Chakrabarti G, Moore ZR, Luo X, et al. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab. 2015;3:12. doi: 10.1186/s40170-015-0137-1
   PubMedGoogle Scholar
• Wang W, Pan H, Ren F, et al. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells. Bioscience Reports query. 2022;42(3). doi: 10.1042/BSR20212171
   Google Scholar
• Xu Y, Yu Z, Fu H, et al. Dual inhibitions on glucose/glutamine metabolisms for nontoxic pancreatic cancer therapy. ACS Appl Mater Interfaces. 2022;14(19):21836–21847. doi: 10.1021/acsami.2c00111
   PubMed Web of Science ®Google Scholar
• Gerber DE, Beg MS, Fattah F, et al. Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br J Cancer. 2018;119(8):928–936. doi: 10.1038/s41416-018-0278-4
   PubMed Web of Science ®Google Scholar
• Buwenge M, Macchia G, Arcelli A, et al. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. J Pain Res. 2018;11:2169–2178. doi: 10.2147/JPR.S167994
   PubMed Web of Science ®Google Scholar
• Zuzčák M, Trnka J. Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review). Int J Oncol. 2022;61(2). doi: 10.3892/ijo.2022.5383
   PubMed Web of Science ®Google Scholar
• Shetty A, Nagesh P, Setua S, et al. Novel paclitaxel nanoformulation impairs de novo lipid synthesis in pancreatic cancer cells and enhances gemcitabine efficacy. ACS Omega. 2020;5(15):8982–8991. doi: 10.1021/acsomega.0c00793
   PubMed Web of Science ®Google Scholar
• Fritz V, Benfodda Z, Rodier G, et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther. 2010;9(6):1740–1754. doi: 10.1158/1535-7163.MCT-09-1064
   PubMed Web of Science ®Google Scholar
• Eser S, Schnieke A, Schneider G, et al. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111(5):817–822. doi: 10.1038/bjc.2014.215
   PubMed Web of Science ®Google Scholar
• Yin X, Xu R, Song J, et al. Lipid metabolism in pancreatic cancer: emerging roles and potential targets. Cancer Commun (Lond). 2022;42(12):1234–1256. doi: 10.1002/cac2.12360
   PubMed Web of Science ®Google Scholar
• Catalina-Rodriguez O, Kolukula VK, Tomita Y, et al. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget. 2012;3(10):1220–1235. doi: 10.18632/oncotarget.714
   PubMedGoogle Scholar
• Dean EJ, Falchook GS, Patel MR, et al. Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640. J Clin Oncol. 2016;34(15_suppl):2512–2512. doi: 10.1200/JCO.2016.34.15_suppl.2512
   Web of Science ®Google Scholar
• Reyes-Castellanos G, Hadi NA, Gallardo-Arriaga S, et al. Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. iScience. 2023;26(6):106899. doi: 10.1016/j.isci.2023.106899
   PubMed Web of Science ®Google Scholar
• Andreasson C, Ansari D, Ekbom F, et al. Macropinocytosis: the Achilles’ heel of pancreatic cancer? Scand J Gastroenterol. 2021;56(2):177–179. doi: 10.1080/00365521.2020.1855471
   PubMed Web of Science ®Google Scholar
• Zhang Y, Commisso C. Macropinocytosis in cancer: a complex signaling network. Trends Cancer. 2019;5(6):332–334. doi: 10.1016/j.trecan.2019.04.002
   PubMed Web of Science ®Google Scholar
• Palm W. Metabolic functions of macropinocytosis. Philos Trans R Soc Lond B Biol Sci. 2019;374(1765):20180285. doi: 10.1098/rstb.2018.0285
   PubMed Web of Science ®Google Scholar
• Davidson SM, Jonas O, Keibler MA, et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat Med. 2017;23(2):235–241. doi: 10.1038/nm.4256
   PubMed Web of Science ®Google Scholar
• Kimmelman AC, White E. Autophagy and tumor metabolism. Cell Metab. 2017;25(5):1037–1043. doi: 10.1016/j.cmet.2017.04.004
   PubMed Web of Science ®Google Scholar
• Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25(7):717–729. doi: 10.1101/gad.2016111
   PubMed Web of Science ®Google Scholar
• Gillson J, El-Aziz Y, Leck L, et al. Autophagy: a key player in pancreatic cancer progression and a potential drug target. Cancers (Basel). 2022;14(14):3528. doi: 10.3390/cancers14143528
   PubMed Web of Science ®Google Scholar
• Liu C, Li C, Liu Y. The role of metabolic reprogramming in pancreatic cancer chemoresistance. Front Pharmacol. 2022;13:1108776. doi: 10.3389/fphar.2022.1108776
   PubMed Web of Science ®Google Scholar
• Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93(1–2):53–62. doi: 10.1016/S0248-4900(01)01125-X
   PubMed Web of Science ®Google Scholar
• Xu R, Yang J, Ren B, et al. Reprogramming of amino acid metabolism in pancreatic cancer: recent advances and therapeutic strategies. Front Oncol. 2020;10:572722. doi: 10.3389/fonc.2020.572722
   PubMed Web of Science ®Google Scholar
• Commisso C, Davidson MS, Soydaner-Azeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497(7451):633–637. doi: 10.1038/nature12138
   PubMed Web of Science ®Google Scholar
• Liu H, Sun M, Liu Z, et al. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. J Control Release. 2019;296:40–53. doi: 10.1016/j.jconrel.2019.01.014
   PubMed Web of Science ®Google Scholar
• Sheng W, Geng J, Li L, et al. An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation. Oncol Rep. 2020;43(3):851–863. doi: 10.3892/or.2020.7468
   PubMed Web of Science ®Google Scholar
• Wang X, Sheng W, Wang Y, et al. A macropinocytosis-intensifying albumin domain-based scFv antibody and its conjugate directed against K-Ras mutant pancreatic cancer. Mol Pharm. 2018;15(6):2403–2412. doi: 10.1021/acs.molpharmaceut.8b00234
   PubMedGoogle Scholar
• Tanouchi A, Taniuchi K, Furihata M, et al. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells. J Exp Clin Cancer Res. 2016;35(1):190. doi: 10.1186/s13046-016-0466-0
   PubMedGoogle Scholar
• Latario CJ, Schoenfeld LW, Howarth CL, et al. Tumor microtubes connect pancreatic cancer cells in an Arp2/3 complex-dependent manner. Mol Biol Cell. 2020;31(12):1259–1272. doi: 10.1091/mbc.E19-11-0605
   PubMed Web of Science ®Google Scholar
• Teranishi F, Takahashi N, Gao N, et al. Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Sci. 2009;100(4):770–777. doi: 10.1111/j.1349-7006.2009.01084.x
   PubMed Web of Science ®Google Scholar
• Zheng YT, Yang H, Li T, et al. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacol Sin. 2015;36(5):614–626. doi: 10.1038/aps.2015.4
   PubMed Web of Science ®Google Scholar
• Lin HP, Singla B, Ghoshal P, et al. Identification of novel macropinocytosis inhibitors using a rational screen of food and drug administration-approved drugs. Br J Pharmacol. 2018;175(18):3640–3655. doi: 10.1111/bph.14429
   PubMed Web of Science ®Google Scholar
• Meng H, Zhao Y, Dong J, et al. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano. 2013;7(11):10048–10065. doi: 10.1021/nn404083m
   PubMed Web of Science ®Google Scholar
• Chen X, Tao Y, He M, et al. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis. Theranostics. 2021;11(18):8692–8705. doi: 10.7150/thno.60437
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Rubinson DA, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;19(6):637–638. doi: 10.1634/theoncologist.2014-0086
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Maring JG. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics. 2013;14(7):799–811. doi: 10.2217/pgs.13.54
   PubMed Web of Science ®Google Scholar
• Raczyński I, Radecka B, Krzakowski M. Survival of pancreatic cancer patients treated with nab-paclitaxel (nab-P) in clinical practice: analysis of national health fund data. Oncol Clin Pract. 2023;19(6):391–397. doi: 10.5603/OCP.2022.0055
   Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):271–284. doi: 10.1016/S0168-3659(99)00248-5
   PubMed Web of Science ®Google Scholar
• Mohammadzadeh V, Rahiman N, Hosseinikhah SM, et al. Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: an update. J Drug Delivery Sci Technol. 2022;73:103459. doi: 10.1016/j.jddst.2022.103459
   Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71–79. doi: 10.1016/j.addr.2012.10.002
   PubMed Web of Science ®Google Scholar
• Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38. doi: 10.1016/j.addr.2018.07.007
   PubMed Web of Science ®Google Scholar
• Hansen AE, Petersen AL, Henriksen JR, et al. Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper-64 liposomes. ACS Nano. 2015;9(7):6985–6995. doi: 10.1021/acsnano.5b01324
   PubMed Web of Science ®Google Scholar
• Grodzinski P, Kircher M, Goldberg M, et al. Integrating nanotechnology into cancer care. ACS Nano. 2019;13(7):7370–7376. doi: 10.1021/acsnano.9b04266
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nature Rev Mater. 2016;1(5):16014. doi: 10.1038/natrevmats.2016.14
   Web of Science ®Google Scholar
• Viegas C, Patricio AB, Prata J, et al. Advances in pancreatic cancer treatment by nano-based drug delivery systems. Pharmaceutics. 2023;15(9):2363. doi: 10.3390/pharmaceutics15092363
   PubMed Web of Science ®Google Scholar
• Liu L, Kshirsagar PG, Gautam SK, et al. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Theranostics. 2022;12(3):1030–1060. doi: 10.7150/thno.64805
   PubMedGoogle Scholar
• Nielsen MF, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol. 2016;22(9):2678–2700. doi: 10.3748/wjg.v22.i9.2678
   PubMed Web of Science ®Google Scholar
• Ansari D, Carvajo M, Bauden M, et al. Pancreatic cancer stroma: controversies and current insights. Scand J Gastroenterol. 2017;52(6–7):641–646. doi: 10.1080/00365521.2017.1293726
   PubMed Web of Science ®Google Scholar
• Tao J, Yang G, Zhou W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021;14(1):14. doi: 10.1186/s13045-020-01030-w
   PubMed Web of Science ®Google Scholar
• Tian C, Clauser KR, Ohlund D, et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci USA. 2019;116(39):19609–19618. doi: 10.1073/pnas.1908626116
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–1461. doi: 10.1126/science.1171362
   PubMed Web of Science ®Google Scholar
• Olson P, Chu GC, Perry SR, et al. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci USA. 2011;108(49):E1275–84. doi: 10.1073/pnas.1111079108
   PubMed Web of Science ®Google Scholar
• Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735–747. doi: 10.1016/j.ccr.2014.04.021
   PubMed Web of Science ®Google Scholar
• Smith NR, Baker D, Farren M, et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res. 2013;19(24):6943–6956. doi: 10.1158/1078-0432.CCR-13-1637
   PubMed Web of Science ®Google Scholar
• Hosoya H, Kadowaki K, Matsusaki M, et al. Engineering fibrotic tissue in pancreatic cancer: a novel three-dimensional model to investigate nanoparticle delivery. Biochem Biophys Res Commun. 2012;419(1):32–37. doi: 10.1016/j.bbrc.2012.01.117
   PubMed Web of Science ®Google Scholar
• Adiseshaiah PP, Crist R, Hook SS, et al. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016;13(12):750–765. doi: 10.1038/nrclinonc.2016.119
   PubMed Web of Science ®Google Scholar
• Craven KE, Gore J, Wilson JL, et al. Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. Oncotarget. 2016;7(1):323–341. doi: 10.18632/oncotarget.6345
   PubMedGoogle Scholar
• Gore J, Craven KE, Wilson JL, et al. TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget. 2015;6(10):7504–7521. doi: 10.18632/oncotarget.3233
   PubMedGoogle Scholar
• Di Maggio F, Arumugam P, Delvecchio FR, et al. Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma. Pancreatology. 2016;16(6):995–1004. doi: 10.1016/j.pan.2016.05.393
   PubMed Web of Science ®Google Scholar
• Wong PP, Demircioglu F, Ghazaly E, et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell. 2015;27(1):123–137. doi: 10.1016/j.ccell.2014.10.015
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr., Shrivastav S, Shand DG, et al. Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. Cancer Res. 1982;42(10):3944–3949.
   PubMed Web of Science ®Google Scholar
• Rath N, Morton JP, Julian L, et al. ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. EMBO Mol Med. 2017;9(2):198–218. doi: 10.15252/emmm.201606743
   PubMed Web of Science ®Google Scholar
• Vennin C, Chin VT, Warren SC, et al. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci Transl Med query. 2017;9(384). doi: 10.1126/scitranslmed.aai8504
   Google Scholar
• Mei XL, Yang Y, Zhang YJ, et al. Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. Am J Cancer Res. 2015;5(11):3311–3324.
   PubMed Web of Science ®Google Scholar
• Haider M, Elsherbeny A, Pittala V, et al. The potential role of sildenafil in cancer management through EPR augmentation. J Pers Med. 2021;11(6):585. doi: 10.3390/jpm11060585
   PubMed Web of Science ®Google Scholar
• Black KL, Yin D, Ong JM, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res. 2008;1230:290–302. doi: 10.1016/j.brainres.2008.06.122
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002;110(4):475–482. doi: 10.1172/JCI0215223
   PubMed Web of Science ®Google Scholar
• Chen X, Jia F, Li Y, et al. Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment. Biomaterials. 2020;246:119999. doi: 10.1016/j.biomaterials.2020.119999
   PubMed Web of Science ®Google Scholar
• Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36(1):25–31. doi: 10.1016/S0735-1097(00)00705-1
   PubMed Web of Science ®Google Scholar
• Seki T, Fang J, Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 2009;100(12):2426–2430. doi: 10.1111/j.1349-7006.2009.01323.x
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater. 2013;12(11):958–962. doi: 10.1038/nmat3792
   PubMed Web of Science ®Google Scholar
• Sun D, Zhou S, Gao W. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano. 2020;14(10):12281–12290. doi: 10.1021/acsnano.9b09713
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Michalaki B, Alevyzaki F, et al. A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res. 2002;22(6b):3583–3588.
   PubMed Web of Science ®Google Scholar
• Schlick K, Kiem D, Huemer F, et al. Non-pegylated liposomal doxorubicin as palliative chemotherapy in pre-treated advanced pancreatic cancer: a retrospective analysis of twenty-eight patients. Technol Cancer Res Treat. 2021;20:15330338211042139. doi: 10.1177/15330338211042139
   Web of Science ®Google Scholar
• Wainberg ZA, Bekaii-Saab T, Boland PM, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase I/II study. Eur J Cancer. 2021;151:14–24. doi: 10.1016/j.ejca.2021.03.028
   PubMed Web of Science ®Google Scholar
• Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815–823. doi: 10.1038/nnano.2011.166
   PubMed Web of Science ®Google Scholar
• Nedelcu A, Mocan T, Grapa C, et al. Recent advances in nanoparticle-mediated diagnosis and the treatment of pancreatic cancer. Int J Mol Sci. 2021;22(15):8060. doi: 10.3390/ijms22158060
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang J, Meng H. Transcytosis - an effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery. Theranostics. 2019;9(26):8018–8025. doi: 10.7150/thno.38587
   PubMed Web of Science ®Google Scholar
• Akashi Y, Oda T, Ohara Y, et al. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. Br J Cancer. 2014;110(6):1481–1487. doi: 10.1038/bjc.2014.49
   PubMed Web of Science ®Google Scholar
• Hu C, Chen X, Huang Y, et al. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability. Sci Rep. 2018;8(1):2274. doi: 10.1038/s41598-018-20715-4
   PubMedGoogle Scholar
• Tanaka HY, Kano MR. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Sci. 2018;109(7):2085–2092. doi: 10.1111/cas.13630
   PubMed Web of Science ®Google Scholar
• Kano MR, Bae Y, Iwata C, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci USA. 2007;104(9):3460–3465. doi: 10.1073/pnas.0611660104
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nature Nanotechnol. 2012;7(6):383–388. doi: 10.1038/nnano.2012.45
   PubMed Web of Science ®Google Scholar
• Beik J, Abed Z, Ghoreishi FS, et al. Nanotechnology in hyperthermia cancer therapy: from fundamental principles to advanced applications. JControlled Release. 2016;235:205–221. doi: 10.1016/j.jconrel.2016.05.062
   PubMed Web of Science ®Google Scholar
• van Rhoon GC, Franckena M, Ten Hagen TLM. A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy. Adv Drug Deliv Rev. 2020;163-164:145–156. doi: 10.1016/j.addr.2020.03.006
   PubMed Web of Science ®Google Scholar
• Lepock JR. Cellular effects of hyperthermia: relevance to the minimum dose for thermal damage. Int J Hyperthermia. 2003;19(3):252–266. doi: 10.1080/0265673031000065042
   PubMed Web of Science ®Google Scholar
• Roti Roti JL. Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperthermia. 2008;24(1):3–15. doi: 10.1080/02656730701769841
   PubMed Web of Science ®Google Scholar
• Hijnen N, Langereis S, Grüll H. Magnetic resonance guided high-intensity focused ultrasound for image-guided temperature-induced drug delivery. Adv Drug Delivery Rev. 2014;72:65–81. doi: 10.1016/j.addr.2014.01.006
   PubMed Web of Science ®Google Scholar
• Hohneck AL, Sadikaj L, Heinemann L, et al. Patients with advanced pancreatic cancer treated with mistletoe and hyperthermia in addition to palliative chemotherapy: a retrospective single-center analysis. Cancers (Basel). 2023;15(20):4929. doi: 10.3390/cancers15204929
   PubMed Web of Science ®Google Scholar
• Maebayashi T, Ishibashi N, Aizawa T, et al. Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment. Oncol Lett. 2017;13(6):4959–4964. doi: 10.3892/ol.2017.6066
   PubMed Web of Science ®Google Scholar
• Hao C, Xu H, Yu L, et al. Heparin: an essential drug for modern medicine. Prog Mol Biol Transl Sci. 2019;163:1–19.
   PubMed Web of Science ®Google Scholar
• Campello E, Ilich A, Simioni P, et al. The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. Br J Cancer. 2019;121(5):359–371. doi: 10.1038/s41416-019-0510-x
   PubMed Web of Science ®Google Scholar
• Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol. 2007;95(6):507–512. doi: 10.1002/jso.20728
   PubMed Web of Science ®Google Scholar
• von Delius S, Ayvaz M, Wagenpfeil S, et al. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost. 2007;98(2):434–439. doi: 10.1160/TH07-01-0004
   PubMed Web of Science ®Google Scholar
• Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American college of cardiology foundation guide to warfarin therapy. Circulation. 2003;107(12):1692–1711. doi: 10.1161/01.CIR.0000063575.17904.4E
   PubMed Web of Science ®Google Scholar
• Nakchbandi W, Muller H, Singer MV, et al. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand J Gastroenterol. 2006;41(9):1095–1104. doi: 10.1080/00365520600575720
   PubMed Web of Science ®Google Scholar
• Bever KM, Sugar EA, Bigelow E, et al. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB (Oxford). 2015;17(4):292–298. doi: 10.1111/hpb.12334
   PubMed Web of Science ®Google Scholar
• Topalovski M, Brekken RA. Matrix control of pancreatic cancer: new insights into fibronectin signaling. Cancer Lett. 2016;381(1):252–258. doi: 10.1016/j.canlet.2015.12.027
   PubMed Web of Science ®Google Scholar
• Chitty JL, Yam M, Perryman L, et al. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nat Cancer. 2023;4(9):1326–1344. doi: 10.1038/s43018-023-00614-y
   PubMedGoogle Scholar
• Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487–505. doi: 10.1038/s41575-020-0300-1
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with folfirinox in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(7):1020–1027. doi: 10.1001/jamaoncol.2019.0892
   PubMed Web of Science ®Google Scholar
• Wang G, Zhou X, Guo Z, et al. The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β. Cancer Biol Ther. 2022;23(1):150–162. doi: 10.1080/15384047.2022.2035629
   PubMed Web of Science ®Google Scholar
• Qin W, Zou J, Huang Y, et al. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. Oncoimmunology. 2020;9(1):1824631. doi: 10.1080/2162402X.2020.1824631
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Itano N. Hyaluronan: a modulator of the tumor microenvironment. Cancer Lett. 2016;375(1):20–30. doi: 10.1016/j.canlet.2016.02.031
   PubMed Web of Science ®Google Scholar
• Cheng XB, Sato N, Kohi S, et al. Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. PLoS One. 2013;8(11):e80765. doi: 10.1371/journal.pone.0080765
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–429. doi: 10.1016/j.ccr.2012.01.007
   PubMed Web of Science ®Google Scholar
• Seki T, Saida Y, Kishimoto S, et al. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. Neoplasia. 2022;30:100793. doi: 10.1016/j.neo.2022.100793
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, MacDonough SL, Philip PA, et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 2019;37(13):1062–1069. doi: 10.1200/JCO.18.01295
   PubMed Web of Science ®Google Scholar
• Tozzi M, Sorensen CE, Magni L, et al. Proton pump inhibitors reduce pancreatic adenocarcinoma progression by selectively targeting H+, K±ATPases in pancreatic cancer and stellate cells. Cancers (Basel). 2020;12(3):640. doi: 10.3390/cancers12030640
   PubMed Web of Science ®Google Scholar
• Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812–3819. doi: 10.1182/blood-2006-07-035972
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317–1324. doi: 10.1158/1078-0432.CCR-05-1634
   PubMed Web of Science ®Google Scholar
• Blair HA. Daunorubicin/Cytarabine liposome: a review in acute myeloid leukaemia. Drugs. 2018;78(18):1903–1910. doi: 10.1007/s40265-018-1022-3
   PubMed Web of Science ®Google Scholar